Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Walker

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 24, 2019
Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola L Lawson, Carly I Dix, Paul W Scorer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 28, 2019
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola L Lawson, Carly I Dix, Paul W Scorer, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2013
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitorChristian Voitenleitner, Renae Crosby, Jill Walker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2014
Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancerNeill Patani, Anita K Dunbier, Helen Anderson, et al.
Archives of Pathology & Laboratory Medicine|November 21, 2018
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial CarcinomaMagdalena Zajac, Anne-Marie Boothman, Yong Ben, et al.
Journal of the Pediatric Infectious Diseases Society|March 27, 2025
Pharmacokinetics and Safety of Single-Dose Sotrovimab in High-Risk Children and Adolescents With Mild-to-Moderate COVID-19Jennifer Moore, Daren Austin, Alicia Aylott, et al.
Journal of Hepatology|January 16, 2026
Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis BJerome Bouquet, Scott D Speer, Alexander Koenig, et al.
Plos One|April 11, 2023
Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in DenmarkTapashi Dalvi, Mette Nørgaard, Jon P Fryzek, et al.
Cancer Epidemiology|July 4, 2021
Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in DenmarkElizabeth Hedgeman, Mette Nørgaard, Tapashi Dalvi, et al.
Cancer Research Communications|March 2, 2023
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay ValidationSophie Wildsmith, Jiabu Ye, April Franks, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 24, 2019
Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola L Lawson, Carly I Dix, Paul W Scorer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 28, 2019
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola L Lawson, Carly I Dix, Paul W Scorer, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2013
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitorChristian Voitenleitner, Renae Crosby, Jill Walker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2014
Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancerNeill Patani, Anita K Dunbier, Helen Anderson, et al.
Archives of Pathology & Laboratory Medicine|November 21, 2018
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial CarcinomaMagdalena Zajac, Anne-Marie Boothman, Yong Ben, et al.
Journal of the Pediatric Infectious Diseases Society|March 27, 2025
Pharmacokinetics and Safety of Single-Dose Sotrovimab in High-Risk Children and Adolescents With Mild-to-Moderate COVID-19Jennifer Moore, Daren Austin, Alicia Aylott, et al.
Journal of Hepatology|January 16, 2026
Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis BJerome Bouquet, Scott D Speer, Alexander Koenig, et al.
Plos One|April 11, 2023
Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in DenmarkTapashi Dalvi, Mette Nørgaard, Jon P Fryzek, et al.
Cancer Epidemiology|July 4, 2021
Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in DenmarkElizabeth Hedgeman, Mette Nørgaard, Tapashi Dalvi, et al.
Cancer Research Communications|March 2, 2023
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay ValidationSophie Wildsmith, Jiabu Ye, April Franks, et al.
Pageof 7